)
Kate Rochlin, PhD
President & COO
IN8bio
Kate has served as our President since January 2025 and Chief Operating Officer since December 2021, previously serving as VP Operations and Innovation since August 2020. IN8bio is a clinical stage gamma-delta T cell company with programs in Oncology and Autoimmune disease. She has 20+ years of expertise in strategic company development & operations, IP, CMC, and clinical manufacturing of advanced therapies. She joined from Curadigm, a Cambridge, MA-based biotechnology company where she served as Chief Business Officer. Dr. Rochlin earned a Ph.D. in Molecular Biology and Genetics from Weill Cornell Medical College in New York City and the Sloan Kettering Institute, and has a BA from the University of Pennsylvania.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}